Dr. Arghavan Almony, MD

Dr. Almony practices at The Eye Surgery Center of the Carolinas in Southern Pines, North Carolina.

Dr. Almony's NPI, 1558465278, was assigned on September 12, 2006. Dr. Almony graduated from Keck School of Medicine of USC in 2004. Dr. Almony's North Carolina license number on file is 2012-00726.

Dr. Almony's primary practice is The Eye Surgery Center of the Carolinas, at 2170 Midland Road, Southern Pines, NC 28387. The practice phone is (919) 295-1221.

Dr. Almony's primary practice is The Eye Surgery Center of the Carolinas in Southern Pines, North Carolina. Dmand AI also links Dr. Almony to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Almony practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Almony's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Almony is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Almony's licenses on file in 3 states: North Carolina, Missouri and North Dakota.

Dmand AI lists age-related macular degeneration, cataract surgery with lens implant, dry eye, inflammation of iris, laser destruction of retinal or choroid lesions, retinal detachment, retinal occlusion and surgical retina and vitreous procedures among the conditions Dr. Almony treats.

CMS data shows 173,016 Medicare services from Dr. Almony across 16 procedure codes in 2024, for 566 Medicare patients. Medicare paid $5,374,831 for them.

CMS counts 566 Medicare patients who saw Dr. Almony in 2024. The largest group is 75 to 84, with 202 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Almony's median patient age at 74, with 58% women.

In 2024, Dr. Almony wrote 253 Medicare Part D claims for 92 patients. 45% of them were for generic drugs. CMS names the drug for 173 of them, across 6 drugs with 11 or more claims each, at $13,523 in total drug cost. In 2023, CMS named 198 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Almony for performance year 2024, reported as part of a group. Dr. Almony accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 27 papers to Dr. Almony, published from 2010 to 2020. 2013 was the busiest year, with 3. The most frequent topics are Bevacizumab, Visual Acuity and Vitrectomy. Dr. Almony has published most often in Retina. Dr. Almony's most frequent co-authors are Gaurav K. Shah, MD, Kevin J. Blinder, MD and Dean Eliott, MD.

Dmand AI links Dr. Almony to 2 clinical trials. Conditions studied include Macular Degeneration, Ocular Hypertension and Eye Diseases.

CMS Open Payments shows 300 general payments to Dr. Almony from 24 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. Genentech, Inc. paid the most, $88,165.

Dmand AI lists 1 award for Dr. Almony, most recently CMS Stage 1 EHR in 2013.

Dr. Almony graduated from Keck School of Medicine of USC in 2004. Dr. Almony is a member of AAO.

Dr. Almony is in network with 24 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 14. Check the plan with the practice before a visit.